Brief: Avacta Reports Updated Phase 1 Clinical Data Of Ava6000 Demonstrating Multiple Ongoing, Durable Responses In Solid Tumors

Avacta

14/09/2024 08:06

Sept 14 (Reuters) - Avacta Group PLC  AVCT.L :
    * AVACTA REPORTS UPDATED PHASE 1 CLINICAL DATA OF AVA6000 AT
THE
EUROPEAN SOCIETY FOR MEDICAL ONCOLOGY (ESMO) CONGRESS
DEMONSTRATING MULTIPLE ONGOING, DURABLE RESPONSES IN SOLID
TUMORS
    * AVACTA GROUP PLC - AVA6000 IS SAFE AND WELL-TOLERATED IN
BOTH
STUDY ARMS: EVERY THREE WEEKS (Q3W) AND EVERY TWO WEEKS (Q2W)
DOSING

Source text for Eikon:  ID:nGNXbCdfby 
Further company coverage:  AVCT.L 

 ((Reuters.Briefs@thomsonreuters.com;))